• contact
  • home
  • about
    • our history
    • management
    • board of directors
    • advisors
  • approach
  • pipeline
  • news & insights
    • presentations
    • press releases
    • references (PRL-02)
    • references (CGS-200-5)
  • careers
  • contact
  • Menu
  • newsworthy &
    insightful

    Stay updated and informed about all things Propella.

Presentation at the 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022): Propella Therapeutics Corporate Presentation

/in presentations /by george

Propella Therapeutics, Inc. participated in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-12-08 17:05:402022-09-12 12:17:50Presentation at the 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022): Propella Therapeutics Corporate Presentation

Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event

/in press releases /by george

Propella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-12-07 09:43:112022-02-15 09:20:10Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event

Presentation at the MedInvest Oncology Conference (December 7-10, 2021): Propella Therapeutics Corporate Presentation

/in presentations /by george

Propella Therapeutics, Inc. presented at the MedInvest Oncology Conference on December 7, 2021.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-12-01 12:22:252022-09-12 12:21:31Presentation at the MedInvest Oncology Conference (December 7-10, 2021): Propella Therapeutics Corporate Presentation

Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index

/in press releases /by george

Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-06-29 15:42:032022-01-04 09:10:09Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index

Presentation at the American Society of Clinical Oncology Annual Meeting (June 4, 2021; San Francisco, CA): A Phase 1/2a, open-label, multicenter study of intramuscular abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114)

/in presentations /by george

Propella Therapeutics, Inc. presented “A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)” at the American Society of Clinical Oncology Annual Meeting in San Francisco, CA on June 4, 2021.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-06-07 20:44:282022-09-12 12:32:10Presentation at the American Society of Clinical Oncology Annual Meeting (June 4, 2021; San Francisco, CA): A Phase 1/2a, open-label, multicenter study of intramuscular abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114)

Press Release: Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment; Appoints Brendan Griffin, MBA as Chief Financial Officer

/in press releases /by george

Propella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-05-19 19:12:482022-01-04 09:10:35Press Release: Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment; Appoints Brendan Griffin, MBA as Chief Financial Officer
Page 2 of 7‹1234›»

categories

  • presentations
  • press releases
  • references (CGS-200-5)
  • references (PRL-02)
  • home
  • about
  • approach
  • pipeline
  • news & insights
  • careers
  • contact
© 2020-2023 Propella Therapeutics, Inc. / all rights reserved
  • privacy policy
  • terms of use
  • copyright policy
Scroll to top